Testing a blood test to guide breast cancer treatment
Part of Cancer clinical trials.
This trial is studying whether a blood test can help doctors choose the right treatment for women with a certain type of breast cancer (HER2-low). It focuses on a common chemotherapy drug (docetaxel) and how well it works based on the blood test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with breast cancer confirmed by a biopsy.
- Your cancer is HER2-low (score 1+ or 2+ but no gene amplification) or HER2-zero (score 0).
- You are 18 years or older.
- You have not had any other cancer in the past.
- You agree to have your medical records used and sign a consent form.
- You are not male, not pregnant or breastfeeding, and no known allergy to T-DXd.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This study tests how well trastuzumab deruxtecan (T-DXd) works for people with HER2-low breast cancer that has spread. The treatment is given as part of routine care, and the trial uses advanced imaging (PET/CT) to measure response.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Hear when a new Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.